Cargando…
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
Background: This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy. Methods: A literature review w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296812/ https://www.ncbi.nlm.nih.gov/pubmed/37366887 http://dx.doi.org/10.3390/curroncol30060404 |
_version_ | 1785063735966040064 |
---|---|
author | Sarfraz, Humaira Saha, Aditi Jhaveri, Khushali Kim, Dae Won |
author_facet | Sarfraz, Humaira Saha, Aditi Jhaveri, Khushali Kim, Dae Won |
author_sort | Sarfraz, Humaira |
collection | PubMed |
description | Background: This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy. Methods: A literature review was performed using MEDLINE/PubMed between August 1996 and February 2023. The reviewed studies are categorized into these categories: current standard of care treatments, targeted therapies, immunotherapy and clinical trials. The current treatment modality for the treatment of advanced pancreatic cancer is mainly systemic chemotherapy. Results: The introduction of polychemotherapy regimens including gemcitabine/nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, folinic acid and fluorouracil) has improved the clinical outcome of advanced pancreatic cancer. For further improvement in clinical outcomes, several novel approaches have been extensively studied in pancreatic cancer. The review discusses the current standard chemotherapy regimen and the novel treatment options in the field. Conclusions: While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options. |
format | Online Article Text |
id | pubmed-10296812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102968122023-06-28 Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma Sarfraz, Humaira Saha, Aditi Jhaveri, Khushali Kim, Dae Won Curr Oncol Review Background: This review aims to describe the systemic treatment options for pancreatic ductal adenocarcinoma and includes a summary of the current treatments as well as the ongoing clinical trials which may be efficacious in the treatment of this aggressive malignancy. Methods: A literature review was performed using MEDLINE/PubMed between August 1996 and February 2023. The reviewed studies are categorized into these categories: current standard of care treatments, targeted therapies, immunotherapy and clinical trials. The current treatment modality for the treatment of advanced pancreatic cancer is mainly systemic chemotherapy. Results: The introduction of polychemotherapy regimens including gemcitabine/nab-paclitaxel and FOLFIRINOX (oxaliplatin, irinotecan, folinic acid and fluorouracil) has improved the clinical outcome of advanced pancreatic cancer. For further improvement in clinical outcomes, several novel approaches have been extensively studied in pancreatic cancer. The review discusses the current standard chemotherapy regimen and the novel treatment options in the field. Conclusions: While there are novel treatments being explored for metastatic pancreatic, it remains a debilitating and aggressive disease with high mortality that warrants continued efforts to advance therapeutic options. MDPI 2023-05-26 /pmc/articles/PMC10296812/ /pubmed/37366887 http://dx.doi.org/10.3390/curroncol30060404 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sarfraz, Humaira Saha, Aditi Jhaveri, Khushali Kim, Dae Won Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title | Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title_full | Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title_fullStr | Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title_short | Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma |
title_sort | review of current systemic therapy and novel systemic therapy for pancreatic ductal adenocarcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296812/ https://www.ncbi.nlm.nih.gov/pubmed/37366887 http://dx.doi.org/10.3390/curroncol30060404 |
work_keys_str_mv | AT sarfrazhumaira reviewofcurrentsystemictherapyandnovelsystemictherapyforpancreaticductaladenocarcinoma AT sahaaditi reviewofcurrentsystemictherapyandnovelsystemictherapyforpancreaticductaladenocarcinoma AT jhaverikhushali reviewofcurrentsystemictherapyandnovelsystemictherapyforpancreaticductaladenocarcinoma AT kimdaewon reviewofcurrentsystemictherapyandnovelsystemictherapyforpancreaticductaladenocarcinoma |